Abstract
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are two inflammatory joint diseases characterized by bone complications including osteoporosis. In RA, periarticular bone loss, bone erosions, and systemic osteoporosis are observed, with an increased risk of fractures. Determinants of fractures are underlying conditions (as RA has a female preponderance and an increased prevalence with age), severity of the disease, and use of glucocorticoids. However, bone loss can occur even in glucocorticoid-naive patients. Prospective data show that the optimal control of inflammation in RA is associated with decrease in structural damage and bone loss. RA illustrates the role of inflammation on bone resorption. In AS, osteoporosis is an early event and vertebral fracture risk is increased. Bone loss is related mainly to inflammation, as the disease can occur in young male adult populations, and glucocorticoids are not used in this disease. However, AS is characterized by progressive stiffness and ankylosis of the spine and illustrates also the potential role of inflammation on local bone formation.
Similar content being viewed by others
References
van Staa TP, Geusens P, Bijlsma WJ, Leufkens HGM, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112
Orstavik RE, Haugeberg G, Uhlig T, Mowinckel P, Falch JA, Halse JI et al (2004) Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis 63:177–182
Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R (2001) Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 60:521–522
Hooyman JR, Melton LJ, Nelson AM, O’Fallon WM, Riggs BL (1984) Fractures after rheumatoid arthritis. Arthritis Rheum 27:1353–1361
Orstavik RE, Haugeberg G, Mowinckel P, Hoiseth A, Uhlig T, Falch JA, Halse JI, Mc Closkey E, Kvien TK (2004) Vertebral deformities in rheumatoid arthritis. Arch Intern Med 164:420–425
de Nijs RNJ, Jacobs JWG, Bijlsma JWJ, Lems WF, Laan RFJM, Houben HHM, ter Borg EJ, Huisman AM, Bruyn GAW, van Oijen PLM, Westgeest AAA, Algra A, Hofman DM, on behalf of the Osteoporosis Working Group of the Dutch Society for Rheumatology (2001) Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology 40:1375–1383
Spector TD, Hall GM, Mc Closkey EV, Kanis JA (1993) Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 306:558
Pell NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801–806
Orstavik RE, Haugeberg G, Uhlig T, Mowinckel P, Falch JA, Halse JI, Kvien T (2005) Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry. Osteoporos Int 16:35–42
Lodder MC, Haugeberg G, Lems WF, Uhlig T, Orstavik RE, Kostense PJ et al (2003) Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo–Truro–Amsterdam (OSTRA) collaborative study. Arthritis Rheum 49:209–215
Lems WF, Jahangier ZN, Jacobs JWG, Bijlsma JWJ (1995) Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 13:293–297
Ursum J, Britsemmer K, van Schaardenburg D, Lips PTA, Dijkmans BAC, Lems W (2009) High prevalence of vertebral deformities in elderly patients with early rheumatoid arthritis. Ann Rheum Dis 68:1512–1513
Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, Frediano B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S (2000) High prevalence of vertebral deformities in elderly patients with early rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 27:2582–2589
Smulders E, Schreven C, Weerdesteyn V et al (2009) Fall incidence and fall risk factors in people with rheumatoid arthritis. Ann Rheum Dis 68:1795–1796
Hayashibara M, Hagino H, Katagiri H, Okano T, Okada J, Teshima R (2010) Incidence and risk factors of falling in ambulatory patients with rheumatoid arthritis: a prospective 1-year study. Osteoporos Int. doi:10.1007/s00198-009-1150-4
Jamison M, Neuberger GB, Miller PA (2003) Correlates of falls and fear of falling among adults with rheumatoid arthritis. Arthritis Rheum 49:673–680
Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B et al (1994) Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 93:2379–2386
Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M, Muller D, Fontaine KR, Bathon JM (2008) Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 59:807–815
Matschke V, Murphy P, Lemmey AB, Maddison PJ, Thom JM (2010) Muscle quality, architecture, and activation in cachetic patients with rheumatoid arthritis. J Rheumatol 37:282–284
Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ (2006) Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 84:1463–1472
Marcora SM, Lemmey AB, Maddison PJ (2005) Can progressive resistance training reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. J Rheumatol 32:1031–1039
Orstavik RE, Haugeberg G, Uhlig T, Falch JA, Halse JI, Hoiseth A, Lilleas F, Kvien TK (2003) Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density. Arthritis Rheum 3:355–360
Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum 43:522–530
Martin JC, Munro R, Campbell MK, Reid DM (1997) Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. Br J Rheumatol 36:43–49
Hall GM, Spector TD, Griffin AJ, Jawad ASM, Hall ML, Doyle DV (1993) The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 36:1510–1516
Sambrook PN, Eisman JA, Champion GD, Yeates MG, Pocock NA, Eberl S (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30:721–728
Kroger H, Honkanen R, Saarikoski S, Alhava E (1994) Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis 53:18–23
Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Reduced bone mineral density in male rheumatoid arthritis patients. Arthritis Rheum 43:2776–2784
Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27
Lodder MC, de Jong Z, Kostense PJ, Molenaar ETH, Staal K, Voskuyl AE, Hazes JMW, Dijkmans BAC, Lems WF (2004) Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 63:1576–1580
Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, de Jonge-Bok JM, Breedveld FC, Dijkmans BAC, Allaart CF, Lems WF (2007) Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 66:1508–1512
Forslind K, Keller C, Svensson B, Hafstrom I (2003) Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheumatol 30:2590–2596
Kroot EJJA, Nieuwenhuizen MG, Waal Malefijt MC de, Riel PLCM van, Pasker-de Jong PCM van, Laan RFJM (2001) Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum 44:1254–1260
Chopin F, Garnéro P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353–357
Haugeberg G, Conaghan PG, Quinn M, Emery P (2009) Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 68:1898–1901
Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BAC, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499
Wijbrandts CA, Klaasen R, Dijkgraaf MGW, Gerlag DM, van Eck-Smit BLF, Tak PP (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68:373–376
Haugeberg G, Strand A, Kvien TK et al (2005) Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo controlled trial. Arch Intern Med 165:1293–1297
Peel NFA, Spittlehouse AJ, Bax DE, Eastell R (1994) Bone mineral density of the hand in rheumatoid arthritis. Arthritis Rheum 5:983–991
Deodhar AA, Brabyn J, Pande I, Scott DL, Woolf AD (2003) Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. Ann Rheum Dis 62:767–770
Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, Conaghan PG, Stewart S, Emery P (2006) Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 65:736–740
Jensen T, Klarlund M, Hansen M, Jensen KE, Podenphant J, Hansen TM, Skjodt H, Hydstrup L (2004) Bone loss unclassified polyarthritis and early rheumatoid arthritis is better detected by digital X-ray radiogrammetry than dual X-ray absorptiometry: relationship with disease activity and radiographic outcome. Ann Rheum Dis 63:15–22
Bottcher J, Pfeil A, Rosholm A, Petrovitch A, Seidl BE, Malich A, Schafer ML, Kramer A, Mentzel HJ, Lehmann G et al (2005) Digital X-ray radiogrammetry combined with semiautomated analysis of joint space widths as a new diagnostic approach in rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Rheum 52:3850–3859
Haugeberg G, Green MJ, Conaghan PG, Quinn M, Wakefield R, Proudman SM, Stewart S, Hensor E, Emery P (2007) Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 66:1513–1517
Hoff M, Haugeberg G, Kvien TK (2007) Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss. Arthritis Res Ther 9:1–8
Alenfeld FE, Diessel E, Brezger M, Sieper J, Felsenberg D, Braun J (2000) Detailed analyses in periarticular osteoporosis in rheumatoid arthritis. Osteoporos Int 11:400–407
Lindqvist E, Jonsson K, Saxne T, Eberhardt K (2003) Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 62:611–616
Hoff M, Haugeberg G, Odegard S, Syversen S, Landewé R, van der Heijde D, Kvien TK (2009) Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis 68:324–329
Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Groenendael JHLM, Mallée C, de Bois MHW, Breedveld FC, Dijkmans BAC, Lems WF (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68:330–336
Boyesen P, Hoff M, Odegard S, Haugeberg G, Syversen SW, Gaarder PI, Okkenhaug C, Kvien TK (2009) Antibodies to cyclic citrillunated protein and ESR predict hand bone loss in patients with RA of short duration. Arthritis Res Ther 11:R103
Stach CM, Bäuerle M, Englbrecht M, Kronke G, Engelke K, Manger B, Schett G (2010) Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum 62:330–339
Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA (2004) Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 50:36–42
Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli M, Oberhollenzer F, Lorenzini R, Redlich K, Axmann R, Zwerina J, Willeit J (2006) High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 166:2495–2501
Ding C, Parameswaran V, Udayan R, Burgess J, Jones G (2008) Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 93:1952–1958
Cauley JA, Danielson ME, Boudreau RM, Forrest KYZ, Zmuda J, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB, for the Health ABC study (2007) Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 22:1088–1095
Charactcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL (2007) Effect of blockade of TNF-α and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res 22:724–729
Cortet B, Flipo RM, Pigny P, Duquesnoy B, Boersma A, Marchandise X, Delcambre B (1998) Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 25:2339–2344
Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P (1998) Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25:1282–1289
Garnéro P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, van der Heijde D, Boonen A, Geusens P (2002) Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis. The Cobra Study. Arthritis Rheum 46:2847–2856
Geusens PP, Landewé RBM, Garnéro P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DMFM, van der Linden S, Boers M (2006) The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54:1772–1777
Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110:1419–1427
Jimenez-Boj E, Redlich K, Türk B, Hanslik-Schnabel H, Wanivenhaus A, Chott A, Smolen JS, Schett G (2005) Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 175:2579–2588
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoproteogerin ligand. Nature 402:304–309
Zaiss MM, Axmann R, Zwerina J, Polzer K, Gückel E, Skapenko A, Schulze-Koops H, Horwood N, Cope A, Schett G (2007) Treg cells suppress ostoclast formation. A new link between the immune system and bone. Arthritis Rheum 56:4104–4112
Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Hermann M, Smolen J, Schett G (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67:1603–1609
Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682
Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM (2006) RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 45:1068–1076
Li C, Wei XQ, Evans B, Jiang W, Aeschlimann D (2008) IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kb (RANK) expression in myeloid precursor cells. Eur J Immunol 38:2845–2854
Herman S, Mueller R, Kronke G, Zwerina J, Redlich K, Hueber A, Gelse H, Neumann E, Mueller-Ladner U, Schett G (2008) OSCAR, a key co-stimulation molecule for osteoclasts, is induced in patients with rheumatoid arthritis. Arthritis Rheum 58:3041–3050
Schett G, Redlich K, Hayer S et al (2003) Osteoproteogerin protects against generalized bon loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48:2042–2051
Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNFα induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligang. J Clin Invest 106:1481–1488
Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J (2010) Interleudin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 69:284–290
Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewé R, Lacey D, Richard WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163
Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 24:1572–1585
Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G (2009) Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 60:2747–2756
Saidenberg-Kermanac’h N, Corrado A, Lemeiter D, de Vernejoul MC, Boissier MC, Cohen-Solal M (2004) TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200–1207
Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P (2009) RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies. Arthritis Res Ther 11:11–15
Haynes D, Crotti T, Weedon H, Slavotinek J, Au V, Coleman M, Roberts-Thomson PJ, Ahern M, Smith MD (2008) Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum 59:911–920
Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R, on behalf of the Denosumab Rheumatoid Arthritis Study Group (2008) Denosumab treatment effects on strutural damage, bone mineral density, and bone turnover in rheumatoid arthritis. Arthritis Rheum 58:1299–1309
Will R, Palmer R, Bhalla AK, Ring F, Calin A (1989) Osteoporosis in early ankylosing spondylitis. A primary pathological event? Lancet ii:1483–1485
Maillefert JF, Aho S, El Maghraoui A, Dougados M, Roux C (2001) Changes in bone density in patients with ankylosing spondylitis: a 2 year follow-up study. Osteoporos Int 12:605–609
Geusens P, Vosse D, van der Heijde DM et al (2001) High prevalence of thoracic vertebral deformities and discal wedging in ankylosing spondylitis patients with hyperkyphosis. J Rheumatol 28:1856–1861
Raltson SH, Urquhart GDK, Bzeski M, Sturrock RD (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 300:563–565
Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21:1877–1882
Donnelly S, Doyle DV, Denton A, Rolfe J, McCloskey EV, Spector TD (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121
Mitra D, Elvins DM, Speden DJ et al (2000) The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 39:85–89
Vosse D, Feidtkeller E, Erlendsson J et al (2004) Clinical vertebral fractures in patients with ankylosing spondylitis. J Rheumatol 31:1981–1985
Feldtkeller E, Vosse D, Geusens P, van der Linden S (2006) Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis. Rheumatol Int 26:234–239
Vosse D, Landewé R, van der Heijde D, van der Linden S, van Staa TP, Geusens P (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case–control study. Ann Rheum Dis 68:1839–1842
Devogelaer JP, Maldague B, Malghem J, Nagant de Deuxchaisnes C (1992) Appendicular and vertebral bone mass in ankylosing spondylitis. Arthritis Rheum 35:1062–1067
Jun JB, Joo KB, Her MY, Kim TH, Bae SC, Yoo DH, Kim SK (2006) Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 33:1637–1641
El Maghraoui A, Borderie D, Edouard R, Roux C, Dougados M (1999) Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J Rheumatol 26:2205–2209
Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 40:882–888
Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, Bezza A, Maghraoui A El (2009) Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 44:772–776
Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32:1290–1298
Obermayer-Pietsch BM, Lange U, Tauber G et al (2003) Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int 14:995–1000
Gratacos J, Collado A, Pons F, Osaba M, Sammarti R, Roqué M et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 42:2319–2324
Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175–182
Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62:347–349
Briot K, Gossec L, Kolta S, Dougados M, Roux C (2008) Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-α treatment. J Rheumatol 35:855–861
Vosse D, Landewé R, Garnéro P, van der Heijde D, van der Linden S, Geusens P (2008) Association of markers of bone – and cartilage – degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology 1-4
MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD (1997) Biomedical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheum 36:50–53
Stupphann D, Ranner M, Krenbeck D et al (2008) Intracellular and surface RANK L are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int 28:987–993
Rauner M, Stupphann D, Haas M, Fert I, Glatigny S, Sipos W, Bréban M, Pietschmann P (2009) The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio. J Rheumatol 36:120–126
Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RGW (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 60:93–102
Lories RJU, Derese I, Luyten FP (2005) Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 115:1571–1579
Lories RJ, Derese I, Ceuppens JL, Luyten FP (2003) Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by pro inflammatory cytokines, and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum 48:2807–2818
Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257–3262
Schett G, Stolina M, Dwyer D, Zack D, Uderhardt S, Krönke G, Kostenuik P, Feige U (2009) Tumor necrosis factor α and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum 60:2644–2654
Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards WG, Krönke G, Schett G (2010) Blockade of dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592–597
Daoussis D, Liossis SNC, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62:150–158
Mc Gonagle D, Wakefield RJ, Tan AL, D’agostino MA, Toumi H, Hayashi K, Emery P, Benjamin M (2008) Distinct topography of erosion and new bone formation in Achilles tendon enthesitis. Implications for understanding the link between inflammation and bone formation in spondylarthritis. Arthritis Rheum 58:2694–2699
Lories RJU, Derese I, De Bari C, Luyten FP (2007) Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 56:489–497
Iwasawa T, Iwasaki K, Sawada T, Okada A, Ueyama K, Motomura S, Harata S, Inoue I, Toh S, Furukawa KI (2006) Pathophysiological role of endothelin in ectopic ossification of human spinal ligaments induced by mechanical stress. Calcif Tissue Int 79:422–430
Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD, Fox JW, Chirgwin JM, Guise TA (2007) Dickkopf homolog 1 mediates endothelin-1 stimulated new bone formation. Mol Endocrinol 21:486–498
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roux, C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 22, 421–433 (2011). https://doi.org/10.1007/s00198-010-1319-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-010-1319-x